Talk:CD19

	This article is within the scope of WikiProject Molecular Biology, a collaborative effort to improve the coverage of Molecular Biology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Molecular BiologyWikipedia:WikiProject Molecular BiologyTemplate:WikiProject Molecular BiologyMolecular Biology articles
???	This article has not yet received a rating on the importance scale.
	This article is supported by the Molecular and Cell Biology task force (assessed as Low-importance).

Untitled[edit]

DFAS —Preceding unsigned comment added by 128.192.23.183 (talk) 17:52, 11 August 2008 (UTC)[reply]

I think something should be mentioned about the use of CD19 as a B cell neoplasm target (most recently as a target for CAR-modified T cells in CLL cf http://www.ncbi.nlm.nih.gov/pubmed/21830940 ) Ulalume (talk) 18:14, 3 November 2011 (UTC)[reply]

Use as immunoconjugate target[edit]

eg in B43-genistein, an anti-CD19 antibody linked to genistein eg for leukemia. : Chen; et al. (1999). "Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies". {{cite journal}}: Cite journal requires |journal= (help); Explicit use of et al. in: |author= (help) - Rod57 (talk) 00:03, 10 June 2013 (UTC)[reply]